Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 102, Issue 3, 2005, Pages 915-920

  Rowlett, James K ^a   Platt, Donna M ^a   Lelas, Snjezana ^a   Atack, John R ^b   Dawson, Gerard R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

Addiction; Anxiety

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA 1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA 2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA 3; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA 5; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; MIDAZOLAM; RECEPTOR SUBTYPE; TRIAZOLAM; UNCLASSIFIED DRUG; ZOLPIDEM; ANXIOLYTIC AGENT; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; MALE; MOTOR PERFORMANCE; MUSCLE RELAXATION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REINFORCEMENT; SEDATION; TRANQUILIZING ACTIVITY; ADDICTION; ANIMAL; ATAXIA; CEBIDAE; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DOSE RESPONSE; DRUG EFFECT; MACACA; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY;

ANIMALIA; PRIMATES;

ANIMALS; ANTI-ANXIETY AGENTS; ATAXIA; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MACACA MULATTA; MALE; MOTOR ACTIVITY; MUSCLE RELAXATION; PROTEIN SUBUNITS; RECEPTORS, GABA-A; SAIMIRI; SUBSTANCE-RELATED DISORDERS;

EID: 14144254686     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0405621102     Document Type: Article

References (15)

1. Griffiths, R. R. & Weerts, E. M. (1999) Psychopharmacology 134, 1-37.
2. Pritchett, D. B., Lüddens, H. & Seeburg, P. H. (1989) Science 245, 1389-1392.
3. Rudolph, U., Crestani, F. & Möhler, H. (2000) Trends Pharmacol. Sci. 22, 188-194.
4. McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) Nat. Neurosci. 3, 587-592.
5. Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H. & Rudolph, W. (2000) Science 290, 131-134.
6. McKernan, R. M. & Whiting, P. J. (1996) Trends Pharmacol. Sci. 19, 139-143.
7. Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) J. Neurosci. 22, 5572-5580.
8. Crestani, F., Keist, R., Fritschy, J.-M., Benke, D., Vogt, K., Prut, L., Blüthmann, H., Möhler, H. & Rudolph, U. (2002) Proc. Natl. Acad. Sci. USA 99, 8980-8985.
9. Carey, G. & Spealman, R. D. (1998) in Current Protocols in Pharmacology, eds. Enna, S., Williams, M., Ferkany, J., Kenakin, T., Porsolt, R. & Sullivan, J. (Wiley, New York), pp. 10.5.1-10.5.15.
10. Platt, D. M., Rowlett, J. K., Spealman, R. D., Cook, J. M. & Ma, C. (2002) Psychopharmacology 164, 151-159.
11. Lelas, S., Rowlett, J. K. & Spealman, R. D. (2001) Psychopharmacology 154, 96-104.
12. Rowlett, J. K., Rodefer, J. S. & Spealman, R. D. (2002) Exp. Clin. Psychopharmacol. 10, 367-375.
13. Lelas, S., Rowlett, J. K., Spealman, R. D., Cook, J. M., Ma, C. & Yin, W. (2002) Psychopharmacology 161, 180-188.
14. Atack, J. R., Hutson, P. H., Collinson, N., Marshall, G., Bentley, G., Moyes, C., Cook, S. M., Collins, I., Wafford, K. A., McKernan, R. M. & Dawson, G. R., Br. J. Pharmacol., in press.
15. Crestani, F., Löw, K., Keist, R., Mandelli, M.-J., Möhler, H. & Rudolph, U. (2001) Mol. Pharmacol. 59, 442-445.